EUVIMEDEUVIMED entdecken
Crossref

Sotatercept (Winrevair) for Pulmonary Arterial Hypertension

The Medical Letter on Drugs and Therapeutics · 2024

DOI: 10.58347/tml.2024.1702a ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2024. Hauptthemen laut MEDLINE: Recombinant Fusion Proteins.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved sotatercept-csrk (Winrevair – Merck), a first-in-class activin signaling inhibitor, to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events in adults with WHO Group 1 pulmonary arterial hypertension (PAH).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Recombinant Fusion ProteinsHumansHypertension, PulmonaryPulmonary Arterial HypertensionAntihypertensive AgentsTreatment Outcome

Stichwörter der Autor:innen

AdcircaAdempasAlyqFlolanLetairisLiqrevOpsumitOpsynviOrenitramRemodulinRevatioTadliqTracleerTyvasoUptravi

Substanzen

Recombinant Fusion ProteinsAntihypertensive Agents

Zitieren

APA

(2024). Sotatercept (Winrevair) for Pulmonary Arterial Hypertension. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2024.1702a

Vancouver

Sotatercept (Winrevair) for Pulmonary Arterial Hypertension. The Medical Letter on Drugs and Therapeutics. 2024. doi:10.58347/tml.2024.1702a

BibTeX
@article{euvimed2024,
  title = {Sotatercept (Winrevair) for Pulmonary Arterial Hypertension},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2024},
  doi = {10.58347/tml.2024.1702a}
}
Kostenlos starten →